We use cookies to understand how our site is used so we can improve it. Necessary cookies are always on. You can accept all, reject all, or choose what to allow. Learn more
Surgical RoboticsIt put the surgeons on the cap table.
Surgical Robotics
It put the surgeons on the cap table.
In 2023 the world bought roughly US$743 million of orthopedic surgical robots — a niche corner of a US$13.7 billion surgical-robotics market that soft-tissue da Vinci dominates. What makes orthopedics distinct is its economics: the robot is a meter placed in a hospital to bill consumables and service on every procedure, and — for the market leaders — to lock the hospital into a far richer implant stream behind it. The structural fault line is open versus closed platforms, and growth is gated by per-country regulatory approval, not patient demand. This is a study of that market through one of its few pure open-platform players, Korea's Curexo.
A robot-assisted joint-replacement procedure. Curexo's CUVIS-joint drives the bone cut autonomously and works with any implant brand — the open architecture that the implant majors, who use the robot to lock surgeons into their own hardware, will not offer. That single design choice is the whole strategy.
In 2023, surgeons worldwide bought about US$743 million of orthopedic surgical robots — machines that drill, ream and cut bone for hip and knee replacement under software control. That is a rounding error inside the broader US$13.7 billion surgical-robotics market of 2025, a market that Intuitive Surgical's soft-tissue da Vinci system dominates with something north of 60% share. Orthopedics is the small, late, structurally distinct corner of robotic surgery — and the more interesting one, because of how it makes money. The robot is rarely the product. It is a meter, placed in a hospital to bill a thin stream of consumables and service on every procedure for the life of the machine, and — for the companies that designed it that way — to lock the hospital into a far richer stream of implants behind it.
That second clause is the whole game. The defining fault line in this market is not price or precision but platform architecture: whether the robot is built open, to run any implant brand, or closed, to run only the manufacturer's own. It is a study of that market — its installed-base economics, its open-versus-closed divide, and the regulatory calendar that gates its growth — through one of the few pure open-platform players inside it, Korea's Curexo, and of why a robot's revenue arrives long after the sale and from somewhere other than the robot.
Orthopedic surgical robots — a niche inside robotic surgery
≈US$743M
The 2023 orthopedic-robot market, against a US$13.7bn (2025) total surgical-robotics market dominated by soft-tissue da Vinci (~60%+ share; da Vinci systems alone ≈US$2.71bn in 2025). Knee replacement is the largest orthopedic application (≈43% of segment revenue, 2023); North America is roughly half of it. Sources: Grand View Research; MarketsandMarkets; GlobalData.
How the market actually earns: the meter, not the machine
To understand where the money sits, follow a single placement. A hospital buys a capital system — orthopedic units are commonly cited around US$0.5–2 million, the multi-port soft-tissue platforms higher still. From that point the machine generates recurring revenue along three lines: a service-and-maintenance contract (roughly US$150,000–250,000 a year per system), an emerging layer of AI-navigation software subscriptions (on the order of US$50,000–100,000 a year), and — the part that recurs on every single case — single-use instrument and consumable kits: cutting tools, optical tracking arrays, fixation pins. Across the surgical-robotics market as a whole, instruments and accessories are now the largest revenue share, larger than capital systems. The razor is sold once; the blades sell forever.
But the deepest margin pool in orthopedics is not on that list at all. It sits one layer behind the robot, in the implant. For the market leaders, the robot exists to pull through hip and knee implants engineered to work only with their own system — and the implant franchise is where the real money compounds. Stryker's knee-and-hip business runs in the billions on the back of its Mako fleet; the consumable-and-service annuity is the thinner pool that anyone without an implant franchise must live on. This single fact sorts the entire competitive field into two camps and explains almost every strategic choice in it.
Revenue layer
Recurrence
Approx. economics
Who captures it
Capital system
One-time
≈US$0.5–2M / unit (ortho)
All platform OEMs
Service & maintenance
Annual
≈US$150–250k / yr / system
All platform OEMs
AI / navigation software
Subscription
≈US$50–100k / yr (emerging)
Platform OEMs
Per-case consumable kits
Every procedure
≈US$1,800–3,500 (soft-tissue); ortho undisclosed
All platform OEMs — the annuity
Implant stream behind the robot
Every procedure
Billions across an installed fleet
Closed-platform majors ONLY
How value accrues across an orthopedic-robot placement. Capital is sold once; service, software and per-case consumables recur. The implant stream — available only to manufacturers that make implants and lock the robot to them — is the deepest pool and the reason platforms are built closed. Per-unit figures are approximate industry ranges; CUVIS-joint's per-case consumable economics are undisclosed. Sources: MarketsandMarkets; Grand View Research; company disclosures.
The deepest margin pool in orthopedic robotics is not the machine — it is this. Closed-platform majors engineer the robot to run only their own implants, turning each placement into a multi-year implant annuity. Open-platform players, who make no implants, forgo this stream entirely and must earn a living on consumables and service alone.
What is pulling demand — and where it goes by 2030
The demand case underneath the market is demographic and durable. The WHO counts roughly 528 million people living with osteoarthritis and about 1.71 billion with musculoskeletal disorders; aging populations convert that burden into hip and knee replacements, and replacements are migrating toward robotic assistance. The penetration curve in knee surgery has been steep: robot-assisted total knee arthroplasty in the United States rose from a fraction of a percent in 2008 to 8.5% by 2020, then roughly 18% of US cases by 2022. Hip is more contested — a conservative nationwide study put robot-assisted total hip arthroplasty at about 6.7% of US cases by 2022, up from 1.2% in 2016. Add the shift of joint surgery into ambulatory surgical centers, surgeon-ergonomics and precision arguments, and AI navigation, and the structural pull is real.
Where it gets unreliable is the forecast. Size the orthopedic-robot market forward to 2030 and the published estimates do not agree — and the disagreement is the story, not a footnote. Grand View Research's base case has the segment reaching about US$1.09 billion by 2030, a 5.7% compound rate measured off a 2024 base. The Business Research Company's higher estimate puts it near US$2.13 billion by 2030 at a 10.8% rate off its own, later base year — nearly double the base case for the same market over a similar window. That spread is not noise; it is a direct readout of how unsettled the penetration assumptions are. The broader surgical-robotics market is forecast more confidently — MarketsandMarkets sees US$27.1 billion by 2030 off US$13.7 billion in 2025, a 14.7% CAGR — but the orthopedic slice inside it remains a genuinely open question.
Forecast
2030 market size
Published CAGR
Base year
Orthopedic robots — Grand View base
≈US$1.09bn
5.7%
2024
Orthopedic robots — TBRC bull
≈US$2.13bn
10.8%
TBRC base
Surgical robots (all) — MarketsandMarkets
≈US$27.14bn
14.7%
2025 (US$13.69bn)
Two houses, one market, a near-2x gap at 2030. These are two independent endpoints for the same year — each drawn by a different house from a different penetration model and reported against its own base year — not points on a single trajectory. Grand View's 5.7% reconciles with the shared 2023 anchor of ≈US$0.74bn; The Business Research Company's 10.8% is its own published figure off a later base, not a rate derived from that anchor. The broader surgical-robotics market is shown for scale. Figures are house forecasts, not NRG estimates. Sources: Grand View Research; The Business Research Company; MarketsandMarkets.
Treat the gap as the honest answer. The two 2030 figures are not points on a single trajectory; they are two independent endpoints for the same year, each built on a different penetration model and reported against its own base, which is exactly why they cannot be read as one line. A separate, US-only academic extrapolation projects robot-assisted knee surgery reaching roughly 70% of US cases by 2030; an older projection put robotic hip at one-in-four by 2025 and two-in-three by 2030. Both sit far above conservative actuals and far above any whole-market revenue CAGR, which is the trap: a penetration curve is a share-of-procedures story, not a market-size story. Robots can take share of surgeries without the dollar market compounding at the same rate, because the capital price falls and the annuity, not the box, is where the growth lives.
Orthopedic-robot market, 2030 — a range, not a point
US$1.1–2.1bn
Grand View base case ≈US$1.09bn (5.7% CAGR, 2024 base) vs The Business Research Company's higher estimate ≈US$2.13bn (10.8% CAGR off its own later base). The near-2x spread reflects unsettled penetration assumptions, not measurement error. The broader surgical-robotics market is forecast at ≈US$27.1bn by 2030 (14.7%). Sources: Grand View Research; The Business Research Company; MarketsandMarkets.
The structural divide: open libraries against closed locks
Strip the market down and it organizes into two archetypes that want opposite things. The closed, implant-locked majors — Stryker's Mako, Zimmer Biomet's ROSA, J&J/DePuy's VELYS, Smith+Nephew's CORI — sell the robot as the front end of an implant franchise; the architecture is deliberately closed because the lock is the point. Mako alone runs on more than 3,000 systems across 46 countries, with over two million cumulative procedures, and reportedly carries roughly two-thirds of Stryker's US knee volume and a third of its US hip. Against them sit the open, implant-agnostic players — THINK Surgical, which markets its TSolution One as the only commercially available open-implant-library total-joint robot; Curexo's CUVIS-joint; and increasingly MicroPort's SkyWalker out of China. The open camp sells freedom from the implant vendor; it gives up the implant margin to do so.
The open camp is also entangled with itself in a way the closed majors are not. THINK Surgical is at once the standard-bearer for the open library and, in the United States and Europe, the distributor for CUVIS-joint — while remaining its competitor in other geographies. That "frenemy" arrangement is characteristic of a sub-scale challenger field: open players lean on each other's channels to reach hospitals the majors already occupy, even as they contest the same accounts elsewhere, which makes route-to-market in this segment a negotiated dependency rather than a wholly owned asset.
The asymmetry is stark, and it shows up even in who gets assessed. When the UK's NICE reviewed orthopedic robots, it evaluated Mako, ROSA, CORI, VELYS and China's SkyWalker — and not CUVIS-joint. Penetration overall is still described as very low, which cuts both ways: enormous headroom, but a market where the incumbents already own the rooms that matter and the open challengers are fighting for clinical credibility one geography at a time.
Platform
Representative systems
Architecture
Monetization model
Stryker Mako
3,000+ systems, 46 countries
Closed / implant-locked
Robot pulls through Stryker implants
Zimmer Biomet ROSA
≈2,000 systems
Closed / implant-locked
Locked to Zimmer implants
J&J DePuy VELYS
31 countries
Closed / implant-locked
Leverages ATTUNE knee franchise
Smith+Nephew CORI
Handheld, ASC-oriented
Closed / implant-locked
Locked to S+N implants
THINK Surgical TSolution One
Open library (markets as only one)
Open / implant-agnostic
Consumable + service annuity; also distributes CUVIS-joint in US/EU
The case in point: a pure open-platform bet
Curexo is worth studying because it is one of the few companies that has taken the open side of this divide all the way. It began as a sleepy Korean medical-device distributor sitting on roughly ₩187 billion of cash against almost no debt, and reassembled itself into an asset-light surgical-robot OEM: it owns the software, the regulatory clearances and the brand for CUVIS-joint and CUVIS-spine, and owns no factory — Korean contract manufacturers build the machines. Its CUVIS-joint runs any implant brand and drives the bone cut autonomously rather than guiding the surgeon's hand. Open and active, against the majors' closed and assisted. The installed base is the asset, and the meter reads about 43,000 cumulative procedures across roughly 100 hospitals in nine-plus countries — up from about 4,000 in 2022 — placing the company's entire robot segment at perhaps US$26 million, around 3% of Mako's fleet.
The open-platform wager, made concrete. Curexo owns the software, the clearances and the brand for CUVIS-joint and CUVIS-spine but no plant; Korean contract manufacturers build the machines. The fixed cost is research and a sales force, not a factory — and the revenue, by design, is the per-case annuity rather than an implant stream.
The strategic crux Curexo embodies is the open platform's central bargain: it forgoes the deep implant margin the majors keep, and must instead earn a living on the thinner consumable-and-service annuity alone. Whether that annuity is large enough is, candidly, not yet measured. Curexo discloses no per-procedure consumable price, so the size of the annuity is directional, not proven. The one piece of evidence that the per-case economics exist at all is a single year: the robot segment swung from a ₩7.1 billion operating loss in FY2024 to a ₩1.28 billion operating profit in FY2025, the year robots first became the company's largest single segment at 49% of revenue — the plurality of the business, though not yet a majority of it. Real in direction; not yet durable in size. Accounting profit that year did not convert to cash, and the first quarter of 2026 relapsed to an operating loss on lower revenue — the candid texture of a business still proving its annuity.
One move is worth reading not as finance but as market signal. In April 2026 Curexo issued a tiny ₩0.5 billion convertible bond — at a premium, with no refixing — to three named orthopedic surgeons. As capital, for a company with ₩187 billion in the bank, it is meaningless. As a governance tell, it is the point: in a market where adoption is decided by surgeon key-opinion-leaders one operating room at a time, binding demand-side clinicians to the equity is a statement about how this business actually grows. The asset is the cumulative-procedure meter, and the meter is turned by surgeons.
Where the annuity is earned. Every procedure on an installed robot meters consumables and service revenue — the open platform's entire income stream. For CUVIS-joint the per-case figure is undisclosed, so the annuity's direction is visible in the FY2025 segment turn, but its durable size is not yet measured.
The real throttle: the approval calendar, not end-demand
The constraint that most shapes this market is one outsiders consistently underweight. Growth for an export-led platform is gated not by patient demand but by per-country regulatory clearance. Every geography is a separate gate — Korea's MFDS, Japan's PMDA, the EU's CE-MDR, the US FDA — and the approval calendar, not the size of the patient pool, sets the pace at which a robot can be sold. Curexo's own sequence reads as a regulatory roadmap: a Korea hip indication in October 2025, a Japan PMDA clearance in 2025 routed through a Kyocera distribution tie, CE-MDR expected in 2026, and a company-reported US FDA clearance in March 2026 — which, in the spirit of honest sourcing, has not yet been matched to a specific FDA database clearance number and should be read as company-reported until it is.
Reimbursement compounds the constraint in an unintuitive way: it offers no premium for using a robot. US Medicare pays the same procedure code whether or not a robot assists, so the machine is a hospital capital-and-marketing decision, not a billing uplift — and coverage is uneven across geographies regardless. A robot therefore has to justify itself on throughput, recruitment and outcomes, not on a richer claim. Layer on the trade dimension — asset-light OEMs like Curexo carry contract-manufacturing capacity, component sourcing and FX exposure rather than implant economics — and the picture is a market whose ceiling is set by regulators and payers, geography by geography, far more than by the underlying tide of arthritic joints.
“A surgical robot is an installed-base annuity wearing the costume of a capital sale. The decisive question in this market is never how advanced the machine is — it is which margin pool the architecture was built to capture, and how many regulatory gates stand between the company and the next country.”
— Nathan Research Group, MedTech Robotics Series N°01
Where the market goes from here
Project the market forward and two things hold at once. Robotic penetration of knee and hip surgery keeps climbing — plausibly toward a majority of US knee cases over the decade — while the dollar value of the orthopedic-robot segment grows far more slowly and far more contestably, somewhere in the wide band between Grand View's ~US$1.1 billion and The Business Research Company's ~US$2.1 billion by 2030. The structural divide hardens rather than dissolves: the closed majors defend the implant lock that funds everything, and the open camp, with deep-pocketed entrants like MicroPort arriving alongside the incumbent THINK Surgical, contests the price-sensitive and implant-neutral hospitals the majors are structurally unwilling to serve on equal terms. For an open-platform player, the future sorts into three market-and-capability paths — defined by what gets cleared and what the annuity proves, not by any price.
Path
What would have to be true in the market
Where the platform lands
The annuity proves out
Key approvals (notably a verified US clearance) land and per-case consumable revenue compounds across a widening installed base.
A durable open-platform alternative to the closed majors.
A regional specialist
The open wedge holds in price-sensitive and implant-neutral markets, but the annuity stays thin and approvals — and partner channels — come slowly.
A niche export player, real but sub-scale against the majors.
Out-engineered
Closed majors cut capital prices and open rivals (MicroPort, THINK Surgical) and even copycats erode the open differentiation faster than the annuity matures.
Squeezed between the implant-funded majors and cheaper open entrants.
Illustrative market-and-execution paths for an open-platform orthopedic-robot player — analytical constructs to frame the question, not forecasts. Each is defined by a market and capability outcome (regulatory progress, the realized annuity, the durability of the open wedge), never by a target valuation.
A caution belongs on the cheeriest reading of installed-base logic. Curexo's strongest export position, a company-reported ~30.7% share in India, sits inside a tiny, fragmenting market of roughly five vendors — and the largest local distributor reportedly reverse-engineered CUVIS-joint, the so-called copycat episode, which means the installed base there proved less sticky than annuity theory assumes. An open platform's openness is itself a vulnerability: the same architecture that frees the hospital from one implant vendor also lowers the wall against imitation. The annuity is only as durable as the switching cost, and in an open library the switching cost is, by construction, lower.
The lesson generalizes past one company and past orthopedics. In any market where the hardware is a delivery vehicle for a recurring stream — printers and ink, glucose monitors and sensors, capital equipment and its consumables — the durable economics belong to whoever captures the deepest recurring pool and raises the cost of leaving it, not to whoever builds the most elegant machine. Orthopedic robotics is simply a vivid case: the closed majors monetize the implant and the lock; the open challengers bet that freedom from the lock is worth more to enough hospitals than the margin they surrender. Which bet pays is decided in operating rooms and regulators' inboxes, country by country — not in any single year's revenue line. Our full brief on the orthopedic surgical-robotics market — the sizing and its dispersion, the value-chain economics, the open-versus-closed competitive map and the regulatory-calendar outlook — is available to download with this article.
Working With Nathan Research Group
Partner With Nathan Research Group
Public filings and market forecasts establish the shape of orthopedic robotics — the installed-base counts, the approval dates, the wide-band 2030 estimates. What they cannot show is what a robotic procedure actually earns per case once the system is placed, how durable an open platform's annuity really is against implant-funded incumbents and cheaper open entrants, and whether a company-reported clearance has converted into paid procedures on the ground. That intelligence lives with the surgeons, reimbursement specialists and operators who install, pay for and compete with these machines — and reaching them, compliantly, is what we do.
Korea’s first dedicated expert network — Seoul, since 2013
Who we put in the room
Surgical-robotics clinical lead
Arthroplasty surgeons who have run CUVIS-joint, Mako and ROSA in the OR — on accuracy, workflow, and whether autonomous cutting changes outcomes or just marketing.
Orthopedic surgeon / KOL (India)
India is the single most important export market. Surgeons in the Meril and Biorad networks read real adoption, the MISSO copycat fallout, and how sticky an installed robot truly is.
Robotic-surgery coverage is uneven by geography. Reimbursement specialists pressure-test whether each new clearance actually converts into paid procedures.
Surgical-robot market structure (open vs closed; THINK Surgical)
Consumable + service annuity; US/EU route via THINK
The orthopedic-robot field sorts by platform architecture. Closed players monetize the implant stream behind the robot; open players forgo it and live on the consumable-and-service annuity — and partly on each other's distribution channels. System counts are company-reported / industry-cited and approximate. Sources: Stryker / MedTech Dive / The Robot Report; Clarivate; THINK Surgical; company disclosures.
The open-platform niche is shared with THINK Surgical — Curexo's distributor in the US and EU and its competitor everywhere else. Insiders read that frenemy dependency.
Med-device unit economics & governance
Per-procedure consumable-and-service economics on an installed base, how cash actually converts in a system-sale model, and the surgeon convertible-bond governance flag.
Asian med-device manufacturing & supply chain
Curexo owns no factories; the robots are built by Korean contract makers and sold abroad. Operators read FX, OEM capacity, and component-supply risk in an asset-light model.
How an engagement works
1Scope
We turn your thesis into a precise expert profile and question set, mapped to the decisions you need to close.
2Source & vet
We screen and compliance-clear each expert — relevance, recency, and the absence of conflicts — before any call.
3Convene & synthesize
We arrange interviews on your timeline and, where useful, deliver written synthesis tied back to your questions.
If your team is evaluating Curexo, the surgical-robotics market, or the broader medical-device sector, tell us the decision you’re trying to make.
A direct reply from a partner, not an intake form.
Based solely on public sources. Nathan Research Group does not request or facilitate material non-public information, and runs every engagement through a documented compliance protocol.
